Palisade Bio Statistics
Total Valuation
Palisade Bio has a market cap or net worth of $4.25 million. The enterprise value is -$6.87 million.
| Market Cap | 4.25M |
| Enterprise Value | -6.87M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Palisade Bio has 936,402 shares outstanding. The number of shares has increased by 166.99% in one year.
| Shares Outstanding | 936,402 |
| Shares Change (YoY) | +166.99% |
| Shares Change (QoQ) | +68.45% |
| Owned by Insiders (%) | 2.89% |
| Owned by Institutions (%) | 10.57% |
| Float | 830,839 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.87 |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -842.94 |
Financial Efficiency
Return on equity (ROE) is -105.40% and return on invested capital (ROIC) is -138.71%.
| Return on Equity (ROE) | -105.40% |
| Return on Assets (ROA) | -87.00% |
| Return on Capital (ROIC) | -138.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.40% in the last 52 weeks. The beta is 1.29, so Palisade Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -82.40% |
| 50-Day Moving Average | 5.48 |
| 200-Day Moving Average | 7.12 |
| Relative Strength Index (RSI) | 43.18 |
| Average Volume (20 Days) | 21,546 |
Short Selling Information
The latest short interest is 27,119, so 2.90% of the outstanding shares have been sold short.
| Short Interest | 27,119 |
| Short Previous Month | 30,115 |
| Short % of Shares Out | 2.90% |
| Short % of Float | 3.26% |
| Short Ratio (days to cover) | 0.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.21M |
| Pretax Income | -13.50M |
| Net Income | -13.50M |
| EBITDA | -13.38M |
| EBIT | -13.49M |
| Earnings Per Share (EPS) | -$23.64 |
Balance Sheet
The company has $11.30 million in cash and $183,000 in debt, giving a net cash position of $11.12 million or $11.87 per share.
| Cash & Cash Equivalents | 11.30M |
| Total Debt | 183,000 |
| Net Cash | 11.12M |
| Net Cash Per Share | $11.87 |
| Equity (Book Value) | 10.06M |
| Book Value Per Share | 10.75 |
| Working Capital | 9.55M |
Cash Flow
| Operating Cash Flow | -10.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.79M |
| FCF Per Share | -$14.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Palisade Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -166.99% |
| Shareholder Yield | -166.99% |
| Earnings Yield | -317.62% |
| FCF Yield | -253.74% |
Analyst Forecast
The average price target for Palisade Bio is $22.50, which is 395.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.50 |
| Price Target Difference | 395.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -1.80% |
Stock Splits
The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |